300298.SZ
Sinocare, Inc.
SZSE · Healthcare · C 制造业 · CN
CNY 18.46
+0.16%Oct 22, 2026, 10:30 UTC
Sinocare reported revenue of RMB 3.84 billion and net profit attributable to shareholders of RMB 372 million for the first three quarters of 2026.
Source:Oct 22, 2026, 10:30 UTC
Sinocare reported third-quarter 2026 revenue of RMB 1.303 billion, up 9.54% year over year, and net profit attributable to shareholders of RMB 150 million, up 395.16%.
Source:Sep 7, 2026, 11:24 UTC
Sinocare announced it received medical device registration certificates from China's NMPA and Hunan Provincial Medical Products Administration, including a new Class III continuous glucose monitoring system (H6-15s) valid from September 4, 2026 to September 3, 2031, for glucose monitoring in diabetic patients aged 2 and above, calibration-free, with up to 15 days of use.
Source:Sep 1, 2026, 09:29 UTC
Sinocare announced that as of August 31, 2026, it had repurchased 9.1776 million shares (1.65% of total share capital) for a total of 149 million yuan through centralized bidding, and will continue its buyback plan.
Source:Aug 18, 2026, 11:56 UTC
Sinocare has launched new products including the S21 atrial fibrillation arm-type blood pressure monitor, and has not yet launched a watch-style blood pressure monitor.
Source: